The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Patterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., et al. (2012) · Nature · doi:10.1038/nature10933 · Cited by 1,967
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
DeRose, Y. S., Wang, G., Lin, Y.-C., Bernard, P. S., Buys, S. S., Ebbert, M. T. W., Factor, R., Matsen, C., Milash, B. A., Nelson, E., et al. (2011) · Nature Medicine · doi:10.1038/nm.2454 · Cited by 1,002
Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1796 · Cited by 856
Maximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0365 · Cited by 649
The Clinical Relevance of Cancer Cell Lines
Gillet, J.-P., Varma, S., & Gottesman, M. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt007 · Cited by 599
Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications
Abel, E. L., Angel, J. M., Kiguchi, K., & DiGiovanni, J. (2009) · Nature Protocols · doi:10.1038/nprot.2009.120 · Cited by 563
(2003) · PubMed · Cited by 523
A mouse model for EML4-ALK -positive lung cancer
Soda, M., Takada, S., Takeuchi, K., Choi, Y. L., Enomoto, M., Ueno, T., Haruta, H., Hamada, T., Yamashita, Y., Ishikawa, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805381105 · Cited by 512
Gillet, J.-P., Calcagno, A. M., Varma, S., Marino, M., Green, L. J., Vora, M. I., Patel, C., Orina, J. N., Eliseeva, T. A., Singal, V., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111840108 · Cited by 477 · cited 4×
“Several studies have demonstrated that although critical genetic ‘‘driver’’ mutations [6] are often retained in tumor cell lines (as discussed further below), the loss of genetic fidelity results in tumor cells lines that more closely resemble each other regardless of tissue origin than the primary tumor from which th…”
BackgroundInfluentialThe role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 2×
“Given the predictive potential for clinical responsiveness, primary tumorgrafts have effectively become avatar models of human cancer in which to conduct synchronous ‘co-clinical trials’ of novel therapeutic agents similar to studies conducted presently with specific GEMMs [27,28].”
BackgroundMethodTobacco Smoke Promotes Lung Tumorigenesis by Triggering IKKβ- and JNK1-Dependent Inflammation
Takahashi, H., Ogata, H., Nishigaki, R., Broide, D. H., & Karin, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.008 · Cited by 438
An In vivo Platform for Translational Drug Development in Pancreatic Cancer
Rubio-Viqueira, B., Jimeno, A., Cusatis, G., Zhang, X., Iacobuzio-Donahue, C., Karikari, C., Shi, C., Danenberg, K., Danenberg, P. V., Kuramochi, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0113 · Cited by 414
Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., Strawn, S., Wick, M. J., Martell, J., & Sidransky, D. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0233 · Cited by 406
Jänne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405
Cancer Modeling in the Modern Era
Van Dyke, T., & Jacks, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00621-9 · Cited by 358
Contributions of Human Tumor Xenografts to Anticancer Drug Development
Sausville, E. A., & Burger, A. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3627 · Cited by 348
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
Kaitin, K. I., & DiMasi, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.286 · Cited by 328
Orthotopic models of cancer for preclinical drug evaluation
Bibby, M. C. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.021 · Cited by 315
Microenvironmental Regulation of Epithelial–Mesenchymal Transitions in Cancer
Gao, D., Vahdat, L. T., Wong, S., Chang, J. C., & Mittal, V. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1223 · Cited by 305
Clonogenic assay with established human tumour xenografts
Fiebig, H. H., Maier, A., & Burger, A. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.009 · Cited by 291
Rheault, T. R., Stellwagen, J. C., Adjabeng, G. M., Hornberger, K. R., Petrov, K. G., Waterson, A. G., Dickerson, S. H., Mook, R. A., Laquerre, S. G., King, A. J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000063 · Cited by 253
Villarroel, M. C., Rajeshkumar, N. V., Garrido-Laguna, I., De Jesus-Acosta, A., Jones, S., Maitra, A., Hruban, R. H., Eshleman, J. R., Klein, A., Laheru, D., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0893 · Cited by 249
The Use of Targeted Mouse Models for Preclinical Testing of Novel Cancer Therapeutics
Olive, K. P., & Tuveson, D. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0436 · Cited by 244
Genetically Engineered Models Have Advantages over Xenografts for Preclinical Studies
Becher, O. J., & Holland, E. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3827 · Cited by 243
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Lovly, C. M., Heuckmann, J. M., de Stanchina, E., Chen, H., Thomas, R. K., Liang, C., & Pao, W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3879 · Cited by 217
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216
Haber, D. A., & Settleman, J. (2007) · Nature · doi:10.1038/446145a · Cited by 203
Hung, K. E., Maricevich, M. A., Richard, L. G., Chen, W. Y., Richardson, M. P., Kunin, A., Bronson, R. T., Mahmood, U., & Kucherlapati, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908682107 · Cited by 198
Dong, X., Guan, J., English, J. C., Flint, J., Yee, J., Evans, K., Murray, N., MacAulay, C., Ng, R. T., Gout, P. W., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2878 · Cited by 188
Translational research: 4 ways to fix the clinical trial
Ledford, H. (2011) · Nature · doi:10.1038/477526a · Cited by 187
Tumor models for efficacy determination
Teicher, B. A. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0391 · Cited by 186
Maintaining differentiated cellular identity
Holmberg, J., & Perlmann, T. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3209 · Cited by 170
Tumor Models for Efficacy Determination
Teicher, B. A. (2008) · AACR Education book · doi:10.1158/aacr.edb-mct-06-0391 · Cited by 154
Do molecularly targeted agents in oncology have reduced attrition rates?
Walker, I., & Newell, H. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2758 · Cited by 130
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes
Singh, M., Murriel, C. L., & Johnson, L. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2786 · Cited by 125 · cited 4×
“Some of the limitations of asynchronous tumor development in GEMMs can be overcome via the use conditionally regulated GEMMs, allowing control of transgene expression in both a temporal and tissue-specific manner [32,33,67,70,71].”
BackgroundMethodInfluentialXenograft models of head and neck cancers
Sano, D., & Myers, J. N. (2009) · Head & Neck Oncology · doi:10.1186/1758-3284-1-32 · Cited by 110
Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective
Singh, M., & Johnson, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0437 · Cited by 98
The R&D Cost of a New MedicinePreprint
Mestre‐Ferrandiz, J., Sussex, J., & Towse, A. (2012) · RePEc: Research Papers in Economics · Cited by 89
Coffee, E. M., Faber, A. C., Roper, J., Sinnamon, M. J., Goel, G., Keung, L., Wang, W. V., Vecchione, L., de Vriendt, V., Weinstein, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2556 · Cited by 81
Cha, M. Y., Lee, K., Kim, M., Song, J. Y., Lee, K. H., Park, J., Chae, Y. J., Kim, Y. H., Suh, K. H., Lee, G. S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26276 · Cited by 80
Animal Models of Stomach Carcinogenesis
Tsukamoto, T., Mizoshita, T., & Tatematsu, M. (2007) · Toxicologic Pathology · doi:10.1080/01926230701420632 · Cited by 79
Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
Luke, J. J., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2197 · Cited by 79
New Strategies for Treatment of ALK-Rearranged Non–Small Cell Lung Cancers
Sasaki, T., & Janne, P. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1404 · Cited by 79
Cancer complexity slows quest for cure
Hayden, E. C. (2008) · Nature · doi:10.1038/455148a · Cited by 74
Mouse orthotopic models for bladder cancer research
Chan, E., Patel, A. R., Heston, W. D. W., & Larchian, W. A. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08577.x · Cited by 73
Practices and Pitfalls of Mouse Cancer Models in Drug Discovery
Kung, A. L. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)96007-2 · Cited by 72
Cheng, M. M., Quail, M. R., Gingrich, D. E., Ott, G. R., Lü, L., Wan, W., Albom, M. S., Angeles, T. S., Aimone, L. D., Cristofani, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0776 · Cited by 70
Self-citationPitter, K. L., Galbán, C. J., Galbán, S., Tehrani, O. S., Li, F., Charles, N. A., Bradbury, M. S., Becher, O. J., Chenevert, T. L., Rehemtulla, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014545 · Cited by 67
Banerjee, S., Manna, S., Saha, P., Panda, C. K., & Das, S. (2005) · European Journal of Cancer Prevention · doi:10.1097/00008469-200506000-00004 · Cited by 58
Tuli, R., Surmak, A. J., Reyes, J., et al. (2012) · Translational Oncology · doi:10.1593/tlo.11316 · Cited by 58
The use of the orthotopic model to validate antivascular therapies for cancer
Loi, M., Paolo, D. D., Becherini, P., Zorzoli, A., Perri, P., Carosio, R., Cilli, M., Ribatti, D., Brignole, C., Pagnan, G., et al. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.103230ml · Cited by 57
Cancer Cell Phenotypes, in Fifty Shades of Grey
Marusyk, A., & Polyák, K. (2013) · Science · doi:10.1126/science.1234415 · Cited by 57
Vucur, M., Roderburg, C., Bettermann, K., Tacke, F., Heikenwälder, M. F., Trautwein, C., & Luedde, T. (2010) · Oncotarget · doi:10.18632/oncotarget.170 · Cited by 52
Tumor Models in Cancer Research
Weiss, W. A., & Chesler, L. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02399-1 · Cited by 51
ElHafeez, S. A., Torino, C., D’Arrigo, G., Bolignano, D., Provenzano, F., Mattace-Raso, F. U. S., Zoccali, C., & Tripepi, G. L. (2012) · Aging Clinical and Experimental Research · doi:10.1007/bf03325249 · Cited by 51
Seavey, M. M., Lu, L. D., Stump, K. L., Wallace, N. H., Hockeimer, W., O’Kane, T. M., Ruggeri, B., & Dobrzański, P. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0951 · Cited by 42
Self-citationTakahashi, M., Hori, M., Mutoh, M., Wakabayashi, K., & Nakagama, H. (2011) · Cancers · doi:10.3390/cancers3010582 · Cited by 39
A New Generation of Mouse Models of Cancer for Translational Research
Abate-Shen, C. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0500 · Cited by 39
Martin, E. S., Belmont, P. J., Sinnamon, M. J., Richard, L. G., Yuan, J., Coffee, E. M., Roper, J., Lee, L., Heidari, P., Lunt, S. Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2307 · Cited by 38
Smith, P. A., Merritt, D., Barr, L., & Thorley‐Lawson, D. A. (2011) · Genes & Cancer · doi:10.1177/1947601912440878 · Cited by 30
Transplantable Syngeneic Rodent Tumors
Corbett, T. H., Polin, L., Roberts, B. J., Lawson, A. J., Leopold, W. R., White, K., Kushner, J., Paluch, J., Hazeldine, S. T., Moore, R. E., et al. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-100-8_3 · Cited by 26
Genetically Modified Mouse Models for Biomarker Discovery and Preclinical Drug Testing
Kucherlapati, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2021 · Cited by 24
SnapShot: Genetic Mouse Models of Cancer
Zender, L., Zuber, J. A., & Lowe, S. W. (2007) · Cell · doi:10.1016/j.cell.2007.05.013 · Cited by 11
Cited by
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
The Role of Resveratrol in Cancer Therapy
Ko, J.-H., Sethi, G., Um, J.-Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., Bishayee, A., & Ahn, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122589 · Cited by 800
Animal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610
Self-citationCurrent and emerging applications of 3D printing in medicine
Liaw, C.-Y., & Guvendiren, M. (2017) · Biofabrication · doi:10.1088/1758-5090/aa7279 · Cited by 604
Generation of lung organoids from human pluripotent stem cells in vitro
Miller, A. J., Dye, B. R., Ferrer-Torres, D., Hill, D. R., Overeem, A. W., Shea, L. D., & Spence, J. R. (2019) · Nature Protocols · doi:10.1038/s41596-018-0104-8 · Cited by 413
Metadata
- Authors
- Ruggeri, B. A., Camp, F., & Miknyoczki, S.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 87
- Issue
- 1
- Pages
- 150-161
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2015187541
- Cited by
- 365
- References
- 87
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.